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Abstract In order to determine the glycosylation pattern
for IgD, and to examine whether there are changes in the
pattern of IgD and IgA1 O-glycosylation in patients with
hyperimmunoglobulinaemia D and periodic fever syn-
drome (HIDS) during acute febrile attacks and during
periods of quiescence, serum was obtained from 20 patients
with HIDS and 20 control subjects. In the HIDS group,
serum was obtained either during an acute febrile episode
(n = 9) or during a period of quiescence (n = 11). The O-
glycosylation proﬁles of native and desialylated IgA1 and
IgD were measured in an ELISA-type system using the
lectins Helix aspersa and peanut agglutinin, which bind to
alternative forms of O-glycan moieties. IgD is more
heavily O-galactosylated and less O-sialylated than IgA1 in
healthy subjects. HIDS is associated with more extensive
O-galactosylation of IgD and a reduction in O-sialylation
of both IgD and IgA1. These changes are present both
during acute febrile attacks and periods of quiescence. The
T cell IgD receptor is a lectin with binding afﬁnity for the
O-glycans of both IgD and IgA1. The observed changes in
IgD and IgA1 O-glycosylation are likely to have a signif-
icant effect on IgD/IgA1–T cell IgD receptor interactions
including basal immunoglobulin synthesis, and possibly
myeloid IgD receptor-mediated cytokine release.
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Introduction
Hyperimmunoglobulinaemia D and periodic fever syn-
drome (HIDS) is one of a group of hereditary periodic
fever syndromes including familial Mediterranean fever
(FMF); TNF-receptor-associated periodic syndrome
(TRAPS); cryopyrin-associated periodic syndrome (CAPS)
[1]. These autoinﬂammatory syndromes are characterised
by recurrent episodes of fever accompanied by diverse
systemic inﬂammatory symptoms which may include
lymphadenopathy, abdominal discomfort, diarrhoea, vom-
iting, chest pain, joint involvement and skin lesions.
Hyperimmunoglobulinaemia D and periodic fever syn-
drome is inherited as an autosomal recessive disorder
caused by partial deﬁciency of the enzyme mevalonate
kinase (MVK), usually as a result of a compound hetero-
zygotic missense mutation in the MVK gene on chromo-
some 12 [2]. MVK catalyses the ATP-dependent
phosphorylation of mevalonate to produce 5-phosphome-
valonate and is a key component in isoprenoid/cholesterol
metabolism. Although the genetic defect has been well
characterised, the mechanism by which a partial deﬁciency
of MVK causes inﬂammatory attacks remains unclear.
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trauma, surgery and stress has led to the suggestion that
regulation of the immune response may be abnormal in
HIDS. There is evidence for defective lymphocyte apop-
tosis in HIDS supporting the notion that there are abnor-
malities of immune regulation and an inability to limit
immunological responses in affected individuals [3].
Hyperimmunoglobulinaemia D and periodic fever syn-
drome is associated with high levels of circulating immu-
noglobulin, in particular IgD ([100 IU/ml or 14 mg/dl)
and, in most patients IgA1 [4, 5]. The pathogenic signiﬁ-
cance of high IgD and IgA1 levels remains unclear, and
while high immunoglobulin levels may simply reﬂect per-
sistent dysregulated immune activation, we hypothesised
that concurrent changes in immunoglobulin structure, in
particular glycosylation, may play a role in potentiating the
generalised inﬂammatory attacks characteristic of HIDS.
Glycosylation plays an important role in production,
maintenance, handling and function of all glycoproteins
and occurs during and immediately after protein synthesis
[6]. There are two distinct forms of protein glycosylation,
N-linked and O-linked. N-linked carbohydrates, linked to
asparagine residues, are by far the most common, and
usually consist of complex, branched chains [7]. Changes
in immunoglobulin N-linked glycosylation are thought to
contribute to the pathogenesis of a variety of autoimmune
diseases including rheumatoid arthritis, SLE, Crohn’s dis-
ease, primary Sjo ¨grens syndrome and psoriatic arthropathy
[8].
O-linked sugars are more commonly associated with
membrane-bound proteins and are less frequently found in
serum proteins. IgA1 and IgD are unusual in that they both
possess both N-linked and O-linked sugars. We and many
others have described a number of changes in IgA1 O-
glycosylation that are important in the pathogenesis of IgA
nephropathy (IgAN) and Henoch Scho ¨nlein nephritis, two
common patterns of glomerulonephritis [9]. Changes in O-
linked galactosylation and sialylation have been shown to
promote IgA1 self aggregation and formation of antigen–
antibody complexes with IgG antibodies directed against
IgA1 hinge epitopes. High circulating levels of polymeric
IgA1 have also been described in HIDS although the
mechanism for this is unknown [5]. Aberrantly, O-gly-
cosylated IgA1 is also more likely to activate complement
and IgA1 O-glycosylation also inﬂuences myeloid IgA
receptor binding and IgA-induced cellular activation.
In order to determine whether O-linked glycosylation of
IgA1 and IgD is abnormal in HIDS and whether changes in
O-glycosylation might potentiate the generalised inﬂam-
matory attacks characteristic of HIDS, we measured the
extent of hinge region O-galactosylation and O-sialylation
of IgA1 and IgD in patients with HIDS both during acute
febrile attacks and during periods of quiescence.
Materials and methods
Subjects
We studied 20 patients with HIDS (11 male, median age 29,
range 18–61 years) and 20 healthy controls (13 male,
median age 35, range 20–55 years). All patients showed the
relevant pathogenic mutations (Table 1) and all participants
gave informed consent for inclusion in the study. Venous
blood was obtained either during an acute febrile episode
(n = 9)orduringaperiodofquiescence(n = 11)andserum
separated and stored in aliquots at -80C until required.
Materials
Unless otherwise stated, all the reagents and materials were
purchased from Sigma Chemical Co., Poole, Dorset, UK.
Polyclonal anti-IgA, anti-IgD and horseradish-peroxidase-
conjugated anti-mouse antibodies, monoclonal anti-IgD
and OPD substrate tablets were obtained from Dako Ltd
(Ely, UK).
Measurement of serum IgA1 and IgD concentrations by
ELISA
Serum levels of IgA1 and IgD were measured using
speciﬁc ELISAs as published previously [10]. In brief,
96-well immunoplates were coated with rabbit anti-human
antibodies to IgA1 and IgD. After washing with PBS
containing an additional 0.4 M NaCl and 0.1% Tween 20,
excess binding sites were blocked with 2% bovine serum
albumin in PBS, plates were washed again and 50 ll
aliquots of standard and test serum samples, diluted in
PBS, were applied to duplicate wells. Standard curves
were set up on each plate, using serial dilutions of a
commercial human immunoglobulin calibrator preparation
(The Binding Site, Birmingham, UK) ranging from 1 lg/
ml to 1 ng/ml IgA1 or IgD. Serum samples were used at
Table 1 Genotypes of study participants
Mevalonate kinase
(MVK) mutations
Number of
patients
V377I/V377I mutation 1
V377I/I268T mutation 6
V377I/H20P mutation 3
V377I/G309S mutation 1
V377I/L39P mutation 1
V377I/W62X mutation 1
V377I/del mutation 5
P167L/I268T mutation 1
P167L/G202R mutation 1
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123pre-optimised dilutions for each assay. After overnight
incubation and further washing, secondary antibodies to
human IgA1 (1:1,000) or IgD (1:250) were added for 2 h,
plates were washed and horseradish peroxidase-conju-
gated anti-mouse immunoglobulin antibody applied to
the plates. Plates were washed and developed with
1,2-phenylenediamine dihydrochloride (OPD)/H2O2 sub-
strate solution and the results read on a densitometer at
492 nm (Titertek Multiscan, ICN Flow). Standard curves
were constructed for each plate and sample values read
from the standard curves, excluding samples which did
not fall on the linear part of the curves; these were
repeated at a more suitable dilution.
Lectin binding assays
In order to compare the O-glycosylation proﬁles of
serum IgA1 and IgD in HIDS and healthy subjects, the
binding of the lectins from Helix aspersa (HA) and pea-
nut agglutinin (PNA) were measured using our previously
published ELISA method [11]. HA recognises terminal O-
linked N-acetylgalactosamine (GalNAc), and samples
with lower terminal galactosylation and sialylation show
higher HA binding. PNA binds to the core 1 disaccharide
Gal-GalNAc, and is extremely inhibited by the presence
of sialic acid. These assays correlate well with other more
precise methods of immunoglobulin O-glycosylation
analysis [12], and provide an excellent screening method
for comparing the O-glycosylation patterns of multiple
test samples.
Immunoplates were coated with anti-IgA1 or anti-IgD,
blocked with BSA and diluted test serum samples applied
to duplicate wells on a series of replicate immunoplates.
We had previously shown that for IgA1, lectin binding was
proportional to IgA1 over a concentration range of 0.1–
100 lg/ml. In preliminary experiments for this study, this
was also shown to be true for IgD lectin binding. There-
fore, the test samples used in these assays were diluted to
achieve IgA1 and IgD concentrations of approximately
1 lg/ml, and replicate plates developed with HA and PNA
lectins, and also with anti-IgA1 or anti-IgD as appropriate,
followed by anti-mouse-HRP as for ELISA. After over-
night incubation and further washing, 50 ll/well-biotinyl-
ated HA and PNA lectins were applied to replicate plates at
1:250 and 1:500 in PBS, respectively, incubated for 90 min
at room temperature, washed again, and lectin binding
detected with 50 ll/well horseradish peroxidase-conju-
gated avidin. The results were expressed as mean absor-
bance at 492 nm of duplicate wells, with each lectin
binding result adjusted for IgA1 or IgD binding absorbance
to correct for minor variations in the immunoglobulin
concentrations of the different samples.
Desialylation of IgA1 and IgD
The presence of terminal sialic acid moieties on the O-
glycans of IgA1 and IgD can mask lectin binding to the
inner chain and confuse interpretation of the results of
these assays. Therefore, we compared lectin binding of
native and desialylated IgA1 and IgD. Replicate immuno-
plates were coated with primary antibodies, blocked, and
diluted serum samples applied as described above. After
allowing capture of IgA1 or IgD for 24 h at 4C, one set of
plates was washed and desialylated with 50 ll/well Clos-
tridium perfringens neuraminidase (New England Biolabs,
Hitchin, UK) at 100 U/ml in 50 mM sodium citrate buffer,
pH 6.0 for 18 h at 37C. A parallel set of plates were left
untreated at 4C as native immunoglobulin. After this step,
the lectin-binding assays were continued exactly as
described above.
Statistical analysis
Serum IgA1 and IgD concentrations and lectin-binding
results for the HIDS and control groups were expressed as
mean ± standard error of the mean (SEM). Unpaired t-
tests were used to compare the two subject groups, and
paired t-tests to compare the lectin binding of native and
desialylated IgA1 and IgD within the subject groups.
Results
Serum IgD and IgA1 levels
Hyperimmunoglobulinaemia D and periodic fever syn-
drome patients had extremely high serum IgD levels
compared to controls (mean lg/ml IgD ± SEM: HIDS
299.9 ± 40.7, controls 3.94 ± 0.54, P\0.001). Serum
IgA1 was also modestly raised in the HIDS group (mean
mg/ml IgA1 ± SEM: HIDS 3.05 ± 0.33, controls
1.56 ± 0.18, P\0.001). Consistent with other reports IgD
levels did not correlate with IgA1 levels and there was no
signiﬁcant difference in serum IgD and IgA1 levels during
a febrile episode compared to periods of remission [4, 5].
O-glycosylation of serum IgD
Helix aspersa (recognises free terminal GalNAc residues)
showed virtually no binding to native IgD from either
healthy subjects or HIDS patients, with no difference
between the groups (Fig. 1a). This indicates either that IgD
carries no O-glycans, or that the O-linked GalNAc is
completely masked by terminal galactose and/or sialic
acid.
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bound to native IgD from both groups, demonstrating that
IgD is O-glycosylated (Fig. 1b). The absence of HA
binding therefore, indicates that the moieties are heavily
galactosylated. Native IgD in HIDS exhibited higher PNA
binding than controls (mean A492 PNA/A492 IgD ± SEM:
HIDS 0.896 ± 0.086, healthy subjects 0.431 ± 0.043,
P\0.001), suggesting that IgD is less O-sialylated in
HIDS.
Desialylation of IgD prior to lectin binding (Fig. 1a, b)
resulted in a signiﬁcantly lower fold increase in both HA
and PNA lectin binding to IgD in HIDS than in healthy
subjects (mean fold increase after desialylation ±
SEM: HA HIDS 2.14 ± 0.096, control 3.07 ± 0.175,
P\0.001; PNA HIDS 2.27 ± 0.22, healthy subjects
4.83 ± 0.55, P\0.001), conﬁrming lower sialylation in
HIDS.
Overall, these results indicate that in HIDS, serum IgD
is more heavily O-galactosylated but less O-sialylated than
in healthy subjects. These changes were present both dur-
ing a febrile attack and convalescence.
O-glycosylation of serum IgA1
Helix aspersa lectin bound to native serum IgA1 in both
HIDS and controls, demonstrating that this isotype is less
completely O-galactosylated than IgD, with more GalNAc
moieties exposed (Fig. 1c). HA binding to native IgA1
was higher in HIDS than controls (mean A492 HA/A492
IgA1 ± SEM: HIDS 0.953 ± 0.051, healthy subjects
0.742 ± 0.036, P = 0.0017).
Peanut agglutinin binding to native IgA1 (Fig. 1d) was
also higher in HIDS than healthy subjects (mean A492
PNA/A492 IgA1 ± SEM: HIDS 0.515 ± 0.065, healthy
subjects 0.202 ± 0.013, P\0.001).
Desialylation of IgA1 increased both HA and PNA
binding and removed the differences between HIDS and
healthy subjects, indicating that the higher HA and PNA
binding of native IgA1 in HIDS is due to differences in O-
sialylation rather than O-galactosylation (Fig. 1c, d). This
reduced O-sialylation is supported by the lower fold
increases in lectin binding to IgA1 after desialylation in
HIDS than in controls (mean fold increase after desialyla-
tion ± SEM: HA HIDS 1.58 ± 0.07, healthy subjects
1.92 ± 0.08, P = 0.028; PNA HIDS 4.62 ± 0.43, healthy
subjects 9.86 ± 0.65, P\0.001). Again, these changes
were present both during a febrile attack and convalescence.
Discussion
There is increasing evidence that changes in the extent of
immunoglobulin glycosylation can play an integral part in
the pathogenesis of a number of immune-mediated
inﬂammatory diseases [8]. We have shown that HIDS is
associated with more extensive O-galactosylation of IgD
and a reduction in O-sialylation of both IgD and IgA1 and
that these changes are present both during acute febrile
attacks and periods of quiescence.
The precise role of serum IgD in health and disease
remains unclear making it difﬁcult to judge the impact of
these changes in IgD O-glycosylation in HIDS [13].
However, we do know that changes in IgA1 O-glycosyla-
tion can make a signiﬁcant impact on IgA1 function [9]. In
isolated human monocytes, IgD from patients with HIDS
has been shown to be a potent inducer of a number of
inﬂammatory cytokines including tumour necrosis factor
alpha (TNF-a), IL-1b, IL-1 receptor antagonist, IL-6, IL-10
and leukemia inhibitory factor [14]. It has been suggested
that uncontrolled secretion of these cytokines could lead to
the intense inﬂammatory response characteristically seen in
HIDS.
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Fig. 1 Lectin binding to the O-glycans of IgD and IgA1 in HIDS and
healthy subjects. Binding of the lectins HA and PNA to native and
desialylated IgD (a and b) and IgA1 (c and d) in patients with HIDS
(open bars) and controls (black bars). Patients with HIDS were
separated into those whose serum samples were collected during a
febrile attack (HIDS-f) and those collected during a period of
quiescence (HIDS-q). HIDS was associated with more extensive O-
galactosylation of IgD and a reduction in O-sialylation of both IgD
and IgA1, and these changes were present both during acute febrile
attacks and periods of quiescence
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123Activation of human monocytes by IgD is mediated
through ill-deﬁned IgD receptors (IgD-R) [13]. The best
characterised IgD-Rs are those expressed by T lympho-
cytes [15]. These receptors preferentially bind IgD immune
complexes, cross-linking by IgD leads to up-regulation of
IgD-R and augmentation of antibody production, and sig-
niﬁcantly, these receptors are upregulated following vac-
cination [15–17]. Binding of IgD to murine and human T
cell IgD-R is dependent on IgD glycosylation suggesting
that the T cell IgD-R is a lectin [18]. In contrast to the
murine IgD-R which binds IgD N-glycans, the human T
cell IgD-R recognises the O-glycans of the IgD hinge
region and is able to bind both IgD and IgA1 [19]. While
IgA1 is capable of binding to the IgD-R it does not up-
regulate IgD-R expression and effectively blocks activation
of T cell IgD-R by IgD [19]. Clearly, changes in the O-
glycosylation state of IgD and IgA1 could have a signiﬁ-
cant impact on afﬁnity for the T cell IgD-R and the balance
of activation and antagonism of IgD-R mediated T cell
activation in HIDS. Any changes in this balance might be
expected to make an impact on T cell orchestrated antibody
production and could underlie the high basal levels of IgD
and IgA1 seen in HIDS.
It has been noted for some time that there is no clear
correlation between serum IgD (and IgA1) levels and the
frequency or severity of febrile attacks, and it has been
suggested that there might be an inhibitory compound that
normally prevents IgD from eliciting an exaggerated
cytokine response [14]. Up-regulation of the T cell IgD-R
with vaccination may provide an alternative explanation. It
is possible that the level of expression of IgD-Rs dictates
the clinical course of febrile attacks and that this is deter-
mined by the balance between serum IgA1 glycoforms
(blocking up-regulation of IgD-R) and IgD glycoforms
(promoting IgD-R up-regulation), and concurrent external
factors (such as vaccination) that are capable of indepen-
dently up-regulating IgD-R expression. IgA1 and IgD
levels in HIDS do not ﬂuctuate in parallel, making the
interplay between IgA1 and IgD glycoforms and IgD-R
expression even more complex [4].
It is not known whether the myeloid IgD-R has similar
properties to the T cell IgD-R but if it is also an O-glycan
speciﬁc lectin then the observed changes in IgD and IgA1
O-glycosylation might also have signiﬁcant effects on IgD-
induced monocyte cytokine release. Further studies of the
glycosylation of IgD and IgA1, and its impact on interac-
tions with myeloid and T cell IgD-Rs will provide a better
understanding of the pathogenesis of HIDS.
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